About American Stem Cell
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
American Stem Cell Frequently Asked Questions (FAQ)
Where is American Stem Cell's headquarters?
American Stem Cell's headquarters is located at 11014 Bar X Trail, Helotes.
What is American Stem Cell's latest funding round?
American Stem Cell's latest funding round is Grant.
How much did American Stem Cell raise?
American Stem Cell raised a total of $2.5M.
Who are the investors of American Stem Cell?
Investors of American Stem Cell include Texas Emerging Technology Fund.
Who are American Stem Cell's competitors?
Competitors of American Stem Cell include Noveome Biotherapeutics, ERYtech Pharma, Aerie, Minerva Biotechnologies, Apitope, Animal Cell Therapies, NGM Biopharmaceuticals, Endocyte, CureTech, Celtaxsys and 42 more.
Compare American Stem Cell to Competitors
Noveome Biotherapeutics is a clinical-stage biopharmaceutical company. It focuses on developing biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. It engages in completing a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects (PEDs). Noveome Biotherapeutics was formerly known as Stemnion. It was founded in 2000 and is based in Pittsburgh, Pennsylvania.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Cell Line Genetics aims to provide services and products to support research institutions, as well as biotechnology and pharmaceutical companies focused on embryonic stem cell and cancer research.
Minerva Biotechnologies developd biochips: nanoparticles coated with functionalized affinity surfaces. Minerva has developed user-friendly nanoparticles that the end user can utilize as a "black box technology". The nanoparticle system can be fully automated and a range of nanoparticles have been developed so that the readout is compatible with existing lab equipment.
Animal Cell Therapies is a biotech firm that aims to improve the lives of animals through thoughtful research and development. The ACT team is focused on developing and delivering cellular treatment and services to customers.
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.